Andrew Muir

NEJM study points to new era in hepatitis C treatment

NEW YORK (June 4, 2009) -- For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

New method to spot brain swelling in young diabetics

A rare swelling of the brain that is nonetheless the most common diabetes-related cause of death for children with the disease could be caught earlier -- potentially saving lives -- if practitioners learn to recognize key signs. Although doctors have long been familiar with major symptoms associated with the deadly complication, they may be missing subtler clues that could tip them off to a problem much sooner, when treatment is most likely to work, says UF pediatric endocrinologist Dr. Arlan Rosenbloom. And now, after poring over dozens of medical records on a hunt for crucial patterns, the researchers have devised a standardized way to screen for these signals at a child's bedside.

African-Americans Respond Poorly to Hepatitis C Treatment

African-Americans have a significantly lower response rate to treatment for chronic hepatitis C than non-Hispanic whites, according to a new study. Some African-Americans ? 19 percent ? did respond to the drug combination of peginterferon alfa-2b and ribavirin. But in non-Hispanic whites with the same disease, the hepatitis C genotype 1 virus strain, 52 percent had no evidence of the virus in their blood six months after completing the drug therapy ? one of the highest response rates ever reported for this therapy.

NEJM study points to new era in hepatitis C treatment

New method to spot brain swelling in young diabetics

African-Americans Respond Poorly to Hepatitis C Treatment

About us

Recommended